A fund located in North America with around $200 million in current AUM will grow to $400 million in assets by the end of 2013. The fund is the venture capital arm of a larger fund with AUM upward of $50 billion. Over the last 12 months, the group has allocated to more than 10 firms, making the VC number one in its region. The firm is currently looking for new opportunities in the life science space within the next 6-9 months. They typically allocate anywhere between $500,000 and $50 million per firm. The group is a lifecycle investor, which allows them to deploy capital throughout a firm’s entire financing lifecycle, and thus participate in every round of financing.

The firm is currently looking for companies in the information provider space, and is particularly interested in healthcare IT firms. The firm has a global investment mandate, but prefers North American targets for allocation.

The firm almost entirely invests in companies that are pre-revenue, but will consider companies that are not cash-flow-positive. The fund will consider firms with products on the market on a discretionary basis, but has no strict requirements in terms of their EBITDA or annual revenue.

A not-for-profit government organization headquartered in Canada is currently looking for new projects in the life sciences space for an allocation round in 2013. The organization was granted investment funds through the Canadian government to promote research and advancement in the life science sector. The firm typically allocates from $1 million and into the tens of millions per project. They are looking for large-scale projects in the biotech R&D space that are developing products based on genomics.

A family office in the Central United States is currently seeking to invest in, acquire or recapitalize small- to middle-market businesses. The firm is a non-traditional private equity fund in that the managers of the fund provide all of its capital. Therefore, there are no hard fund investment periods, and they are free to hold and operate portfolio companies with a very long-term perspective if required. The firm operates on an opportunistic basis and makes allocations on a case-by-case basis. They will typically invest into the tens of millions in a potential issuer. Within the life sciences and healthcare space, the partnership seeks contract manufacturing and service provider firms; they are especially interested at this time in service providers such as CRO’s and CMO’s.

A private equity group that invests in the life sciences space based in the Eastern US with nearly $2 billion in AUM is currently looking for new firms for potential investments for their third fund, which targeted $650 million, and currently has $350 million in dry powder to deploy to new firms over the next year or so. The firm typically allocates $20-50 million per firm, and is currently looking for firms that are seeking growth capital. The firm is interested in medtech and biotech therapeutic and diagnostic companies. The firm is very opportunistic and will look at the full gamut of subsectors. In the biotech therapeutics and diagnostics space, the fund is most interested in firms focused on infectious diseases, cardiovascular disorders, and pediatrics. They are looking for firms that have products in phase I or II of clinical trials. The firm invests in companies based globally.

A highly opportunistic, London-based private investor backed by a single family office LP in the life sciences space is interested in making 2-4 allocations over the coming six months. Within life sciences, the firm has no specific criteria for investment and will look at opportunities regardless of sector, indication, development phase or financing round. The firm has comfortably made allocations from seed stage financings to multi-million dollar, late-stage investments. The firm has a very long-term orientation and has the capital available to make several follow-on equity capitalizations for subsequent rounds.

A private equity group based in the Eastern US has over $250 million in total assets under management, has raised three funds, and is currently looking for new investment opportunities in the life sciences space. While the firm has no set time frame to make an investment, they would allocate to a firm within the next 3-6 months if a compelling opportunity were identified. The group typically invests around $5-20 million per company.

Currently, they are looking for firms within the R&D services space. The firm is most interested in analytical services companies, as well as contract research organizations (CROs) that specialize in toxicology, however would consider other companies that fall within the umbrella of the biotech R&D services space as well.

This PE group executes recapitalization, growth equity, and buyout transactions. The firm is only interested in companies that are cash flow positive. With that being said, the firm is looking for firms whose EBITDA is in the $1-10 million range, and has annual revenue that does not exceed $75 million.

A family office located in the Western US with around $100 million in assets is looking for a compelling opportunity for allocation within the next 6-9 months. The office invested in more than five deals in 2012, typically between $1-5 million per firm.

The foundation is most interested in medical devices, and will look at firms within the full gamut of medtech subsectors. Typically, the office allocates to firms that have at least one product on the market. They have no strict criteria in terms of a firm’s EBITDA or revenue, but require that any firm in which they invest has goals to lower the cost of healthcare.